Physician profile
Adil Asaduddin
NPI 1538199708
$8,259.52
in general payments reported to CMS, 2019-2025
45 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $322 · 2021: $726 · 2022: $912 · 2023: $1,636 · 2024: $1,477 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,753 · Education: $79.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,753.06 |
| Education | $79.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.16 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Novo Nordisk INC | $1,067.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $769.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.64 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $512.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $502.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.20 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Amgen INC. | $419.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $388.55 | 2019-2025 | |
| Exact Sciences Corporation | $350.47 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $268.79 | 2021-2025 | |
| Allergan, INC. | $218.98 | 2019-2020 | |
| Abbott Laboratories | $171.05 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $94.90 | 2019-2022 | |
| Astellas Pharma US INC | $89.34 | 2019-2023 | Veozah |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Asaduddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.